Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences, Inc.

Collaboration Revenue

Collaboration Revenue %Chg

Collaboration Revenue Common Size

Research and Development

Research and Development %Chg

Research and Development Common Size

General and Administrative

General and Administrative %Chg

General and Administrative Common Size

Total Operating Expenses

Total Operating Expenses %Chg

Total Operating Expenses Common Size

Loss from Operations

Loss from Operations %Chg

Loss from Operations Common Size

Interest Income

Interest Income %Chg

Interest Income Common Size

Interest Expense

Interest Expense %Chg

Interest Expense Common Size

Change in Fair Value of Preferred Warrant Liability

Change in Fair Value of Preferred Warrant Liability %Chg

Change in Fair Value of Preferred Warrant Liability Common Size

Other Income

Other Income %Chg

Other Income Common Size

Total Other Income

Total Other Income %Chg

Total Other Income Common Size

Net Loss

Net Loss %Chg

Net Loss Common Size

Net Loss per Share, Basic and Diluted

Net Loss per Share, Basic and Diluted %Chg

Net Loss per Share, Basic and Diluted Common Size

Weighted-Average Shares Outstanding, Basic and Diluted

Weighted-Average Shares Outstanding, Basic and Diluted %Chg

Weighted-Average Shares Outstanding, Basic and Diluted Common Size

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Interest and Investment Income

Interest and Investment Income %Chg

Interest and Investment Income Common Size

Non-Operating Income

Non-Operating Income %Chg

Non-Operating Income Common Size

Total Non-Operating Income

Total Non-Operating Income %Chg

Total Non-Operating Income Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Consolidated Net Income

Consolidated Net Income %Chg

Consolidated Net Income Common Size

Net Income Attributable to Common Shareholders

Net Income Attributable to Common Shareholders %Chg

Net Income Attributable to Common Shareholders Common Size

Basic EPS

Basic EPS %Chg

Basic EPS Common Size

Diluted EPS

Diluted EPS %Chg

Diluted EPS Common Size

Basic Weighted Average Shares Outstanding

Basic Weighted Average Shares Outstanding %Chg

Basic Weighted Average Shares Outstanding Common Size

Total Shares Outstanding

Total Shares Outstanding %Chg

Total Shares Outstanding Common Size

Diluted Weighted Average Shares Outstanding

Diluted Weighted Average Shares Outstanding %Chg

Diluted Weighted Average Shares Outstanding Common Size

EBITDA

EBITDA %Chg

EBITDA Common Size

Revenue

EBIT

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Total Revenues	20.9	10.7	8.9	10.9	10.1	10.6
Total Revenues %Chg	106.3%	1.2%	-17.9%	14%	-0.2%	8.2%
Collaboration Revenue
Gross Profit	20.9	10.7	8.9	10.9	10.1	10.6
Gross Profit Margin	100%	100%	100%	100%	100%	100%
Selling, General & Administrative Expenses	145.1	122.1	105.9	86.2	74	64.5
General and Administrative
Research & Development Expenses	488.2	410.4	336.3	303.6	260.8	231.3
Research and Development
Operating Profit	-612.5	-521.8	-433.3	-378.9	-324.7	-285.2
Loss from Operations
Operating Margin	-2,934.9%	-4,863.3%	-4,853.4%	-3,477.4%	-3,209.4%	-2,690.6%
Interest and Investment Income	63.9	67.2	64.6	56.9	44.8	33.1
Interest Income
Interest Expense	—	—	—	—	—	—
Interest Expense
Non-Operating Income	1.3	1.1	0.6	0.2	0.6	0.3
Change in Fair Value of Preferred Warrant Liability
Other Income
Total Non-Operating Income	65.2	68.3	65.2	57.1	45.3	33.4
Income Before Provision for Income Taxes	-547.3	-453.5	-368.1	-321.8	-279.4	-251.8
Consolidated Net Income	-547.3	-453.5	-368.1	-321.8	-279.4	-251.8
Net Income Attributable to Common Shareholders	-549.8	-455.7	-369.2	-322.3	-280.5	-252.4
Net Loss
Basic EPS	-4.2	-3.6	-3	-2.9	-2.9	-2.9
Diluted EPS	-4.2	-3.6	-3	-2.9	-2.9	-2.9
Basic Weighted Average Shares Outstanding	131.3	127.7	122	111.6	98.4	86.1
Total Shares Outstanding	146.8	120.8	120.5	119.9	118.9	109.3
Diluted Weighted Average Shares Outstanding	131.3	127.7	122	111.6	98.4	86.1
EBITDA	-609.1	-518.7	-430.3	-376.2	-322	-282.7